HRP20230604T1 - Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate - Google Patents
Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate Download PDFInfo
- Publication number
- HRP20230604T1 HRP20230604T1 HRP20230604TT HRP20230604T HRP20230604T1 HR P20230604 T1 HRP20230604 T1 HR P20230604T1 HR P20230604T T HRP20230604T T HR P20230604TT HR P20230604 T HRP20230604 T HR P20230604T HR P20230604 T1 HRP20230604 T1 HR P20230604T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- integer
- bond
- hydrogen
- chelator
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims 5
- 229940121896 radiopharmaceutical Drugs 0.000 title 1
- 239000012217 radiopharmaceutical Substances 0.000 title 1
- 230000002799 radiopharmaceutical effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000002947 alkylene group Chemical group 0.000 claims 12
- 239000002738 chelating agent Substances 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 239000002184 metal Substances 0.000 claims 8
- 230000002285 radioactive effect Effects 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 229910052717 sulfur Chemical group 0.000 claims 4
- 239000011593 sulfur Chemical group 0.000 claims 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0487—Metallocenes, i.e. complexes based on a radioactive metal complexed by two cyclopentadienyl anions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (11)
1. Spoj kojeg prikazuje formula 1, njegov stereoizomer, njegov hidrat, ili njegova farmaceutski prihvatljiva sol:
[image]
,
naznačen time što u formuli 1:
L1 je -(CH2)a-, gdje je a cijeli broj od 1-8;
U je veza ili -C(O)-;
R1 je -L5-CO2H, gdje je L5 -(CH2)b-, gdje je b cijeli broj od 1-6;
X je veza ili -C(O)-;
W je veza ili -NA1-, A1 je vodik ili -(CH2)c-piridil, gdje je c cijeli broj od 0-3;
L2 je veza ili -(CH2)d-, gdje je d cijeli broj od 1-8;
Tz je veza,
[image]
ili
[image]
;
L3 je C1-12 nerazgranati ili razgranati alkilen, gdje se jedan ili više atoma ugljika u alkilenu može zamijeniti atomima kisika;
L4 je -(CH2)e-, gdje je e cijeli broj od 1-6;
n je cijeli broj od 0-1;
R2 je vodik, C1-5 nerazgranati ili razgranati alkil ili halogen;
Y je kisik ili sumpor;
Z je kelator koji sadrži radioaktivni metal, gdje je radioaktivni metal Ga-68, Cu-64, Cu-67, Y-90, Sc-47, In-111, Sn-117m, Lu-177, Bi-212, Bi-213, Pb-212, Ra-223 ili Ac-225, a kelator je
[image]
,
[image]
,
[image]
,
[image]
ili
[image]
.
2. Spoj, njegov stereoizomer, njegov hidrat, ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time što:
L1 je -(CH2)a-, gdje je a cijeli broj od 1-6;
U je veza ili -C(O)-;
R1 je -L5-CO2H, gdje je L5 -(CH2)b-, gdje je b cijeli broj od 1-4;
X je veza ili -C(O)-;
W je veza ili -NA1-, A1 je vodik ili -(CH2)c-piridil, gdje je c cijeli broj od 0-1;
L2 je veza ili -(CH2)d-, gdje je d cijeli broj od 1-6;
Tz je veza,
[image]
ili
[image]
;
L3 je C1-10 nerazgranati ili razgranati alkilen, gdje se jedan ili više atoma ugljika u alkilenu može zamijeniti atomima kisika;
L4 je -(CH2)e-, gdje je e cijeli broj od 2-4;
n je cijeli broj od 0-1;
R2 je vodik, C1-3 nerazgranati ili razgranati alkil ili halogen;
Y je kisik ili sumpor;
Z je kelator koji sadrži radioaktivni metal, gdje je radioaktivni metal Ga-68, Cu-64, Cu-67, Y-90, Sc-47, In-111, Sn-117m, Lu-177, Bi-212, Bi-213, Pb-212, Ra-223 ili Ac-225, a kelator je
[image]
,
[image]
,
[image]
,
[image]
ili
[image]
.
3. Spoj, njegov stereoizomer, njegov hidrat, ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time što:
L1 je -(CH2)a-, gdje je a cijeli broj od 2-4;
U je veza ili -C(O)-;
R1 je -L5-CO2H, gdje je L5 -(CH2)b-, gdje je b cijeli broj od 1-2;
X je veza ili -C(O)-;
W je veza ili -NA1-, gdje A1 je vodik ili piridil;
L2 je veza ili -(CH2)d-, gdje je d cijeli broj od 1-2;
Tz je veza,
[image]
ili
[image]
;
L3 je C1-8 nerazgranati alkilen, gdje se jedan ili više atoma ugljika u alkilenu može zamijeniti atomima kisika;
L4 je -(CH2)3-;
n je cijeli broj od 0-1;
R2 je vodik, metil ili halogen;
Y je kisik;
Z je kelator koji sadrži radioaktivni metal, gdje je radioaktivni metal Ga-68, Cu-64 ili Lu-177, a kelator može biti
[image]
.
4. Spoj, njegov stereoizomer, njegov hidrat, ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time što se spoj kojeg prikazuje formula 1 bira iz skupine koju čine sljedeći spojevi:
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
,
gdje je u gore prikazanim formulama M radioaktivni metal, gdje je radioaktivni metal u skladu s patentnim zahtjevom 1.
5. Spoj kojeg prikazuje formula 2, njegov stereoizomer, njegov hidrat, ili njegova farmaceutski prihvatljiva sol:
[image]
,
naznačen time što u formuli 2:
L1 je -(CH2)a-, gdje je a cijeli broj od 1-8;
U je veza ili -C(O)-;
R1 je -L5-CO2H, gdje je L5 -(CH2)b-, gdje je b cijeli broj od 1-6;
X je veza ili -C(O)-;
W je veza ili -NA1-, gdje je A1 vodik ili -(CH2)c-piridil, gdje je c cijeli broj od 0-3;
L2 je veza ili -(CH2)d-, gdje je d cijeli broj od 1-8;
Tz je veza,
[image]
ili
[image]
;
L3 je C1-12 nerazgranati ili razgranati alkilen, gdje se jedan ili više atoma ugljika u alkilenu može zamijeniti atomima kisika;
L4 je -(CH2)e-, gdje je e cijeli broj od 1-6;
n je cijeli broj od 0-1;
R2 je vodik, C1-5 nerazgranati ili razgranati alkil ili halogen;
Y je kisik ili sumpor;
Z’ je kelator, a kelator je
[image]
,
[image]
,
[image]
,
[image]
ili
[image]
.
6. Spoj, njegov stereoizomer, njegov hidrat, ili farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 5, naznačen time što:
L1 je -(CH2)a-, gdje je a cijeli broj od 1-6;
U je veza ili -C(O)-;
R1 je -L5-CO2H, gdje je L5 -(CH2)b-, gdje je b cijeli broj od 1-4;
X je veza ili -C(O)-;
W je veza ili -NA1-, gdje je A1 vodik ili -(CH2)c-piridil, gdje je c cijeli broj od 0-1;
L2 je veza ili -(CH2)d-, gdje je d cijeli broj od 1-6;
Tz je
[image]
ili
[image]
;
L3 je C1-10 nerazgranati ili razgranati alkilen, gdje se jedan ili više atoma ugljika u alkilenu može zamijeniti atomima kisika;
L4 je -(CH2)e-, gdje je e cijeli broj od 2-4;
n je cijeli broj od 0-1;
R2 je vodik, C1-3 nerazgranati ili razgranati alkil ili halogen;
Y je kisik ili sumpor;
Z’ je kelator, a kelator je
[image]
,
[image]
,
[image]
,
[image]
ili
[image]
.
7. Spoj, njegov stereoizomer, njegov hidrat, ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 5, naznačen time što:
L1 je -(CH2)a-, gdje je a cijeli broj od 2-4;
U je veza ili -C(O)-;
R1 je -L5-CO2H, gdje je L5 -(CH2)b-, gdje je b cijeli broj od 1-2;
X je veza ili -C(O)-;
W je veza ili -NA1-, gdje je A1 vodik ili piridil;
L2 je veza ili -(CH2)d-, gdje je d cijeli broj od 1-2;
Tz je veza,
[image]
ili
[image]
;
L3 je C1-8 nerazgranati alkilen, gdje se jedan ili više atoma ugljika u alkilenu može zamijeniti atomima kisika;
L4 je -(CH2)3-;
n je cijeli broj od 0-1;
R2 je vodik, metil ili halogen;
Y je kisik;
Z’ je kelator, a kelator je
[image]
.
8. Spoj, njegov stereoizomer, njegov hidrat, ili farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 5, naznačen time što se spoj kojeg prikazuje formula 2 bira iz skupine koju čine sljedeći spojevi:
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
;
[image]
.
9. Pripravak, naznačen time što sadrži spoj, njegov stereoizomer, njegov hidrat, ili njegovu farmaceutski prihvatljivu sol u skladu s patentnim zahtjevom 1 kao aktivni sastojak namijenjen upotrebi u dijagnosticiranju raka prostate.
10. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što pripravak dijagnosticira rak prostate selektivnim vezanjem spoja na PSMA (membranski antigen specifičan za prostatu), hipereksprimiran na stanicama raka prostate.
11. Farmaceutski pripravak, naznačen time što sadrži spoj, njegov stereoizomer, njegov hidrat, ili njegovu farmaceutski prihvatljivu sol u skladu s patentnim zahtjevom 1 kao aktivni sastojak namijenjen upotrebi u sprječavanju ili liječenju raka prostate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180037226 | 2018-03-30 | ||
| EP19775196.9A EP3778592B1 (en) | 2018-03-30 | 2019-03-29 | Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer |
| PCT/KR2019/003716 WO2019190266A1 (ko) | 2018-03-30 | 2019-03-29 | 전립선암 진단 및 치료를 위한 psma-표적 방사성의약품 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230604T1 true HRP20230604T1 (hr) | 2023-09-29 |
Family
ID=68058285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230604TT HRP20230604T1 (hr) | 2018-03-30 | 2019-03-29 | Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US11931431B2 (hr) |
| EP (1) | EP3778592B1 (hr) |
| JP (1) | JP7094591B2 (hr) |
| KR (1) | KR102156385B1 (hr) |
| CN (1) | CN112004812B (hr) |
| AU (1) | AU2019243408B2 (hr) |
| BR (1) | BR112020019566A2 (hr) |
| CA (1) | CA3094620C (hr) |
| CL (1) | CL2020002510A1 (hr) |
| DK (1) | DK3778592T3 (hr) |
| EA (1) | EA202092333A1 (hr) |
| ES (1) | ES2947748T3 (hr) |
| FI (1) | FI3778592T3 (hr) |
| HR (1) | HRP20230604T1 (hr) |
| HU (1) | HUE062904T2 (hr) |
| LT (1) | LT3778592T (hr) |
| MX (1) | MX2020010266A (hr) |
| MY (1) | MY197419A (hr) |
| PH (1) | PH12020551471A1 (hr) |
| PL (1) | PL3778592T3 (hr) |
| PT (1) | PT3778592T (hr) |
| RS (1) | RS64296B1 (hr) |
| SG (1) | SG11202009649RA (hr) |
| SI (1) | SI3778592T1 (hr) |
| WO (1) | WO2019190266A1 (hr) |
| ZA (1) | ZA202006008B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102269315B1 (ko) * | 2019-10-24 | 2021-06-24 | 서울대학교산학협력단 | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |
| US20230016265A1 (en) * | 2019-10-29 | 2023-01-19 | The Cleveland Clinic Foundation | Psma-targeting imaging agents |
| KR20220006286A (ko) | 2020-07-08 | 2022-01-17 | 한국원자력의학원 | 전립선암 진단 및 치료를 위한 전립선특이 막 항원 표적 화합물 및 이를 포함하는 전립선암 진단 및 치료용 조성물 |
| KR20230050552A (ko) * | 2021-10-07 | 2023-04-17 | (주)퓨쳐켐 | 가돌리늄 화합물 및 이를 포함하는 전립선암의 진단 및 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013022797A1 (en) * | 2011-08-05 | 2013-02-14 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
| US9636413B2 (en) * | 2012-11-15 | 2017-05-02 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
| WO2014110372A1 (en) | 2013-01-14 | 2014-07-17 | Molecular Insight Pharmaceuticals | Triazine based radiopharmaceuticals and radioimaging agents |
| MX2016005013A (es) | 2013-10-18 | 2017-02-28 | Deutsches Krebsforsch | Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata. |
| CA3215134A1 (en) * | 2014-05-06 | 2015-11-12 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| PT3925952T (pt) * | 2016-03-22 | 2023-12-13 | Univ Johns Hopkins | Agentes alvo de alta afinidade direcionados ao antigénio de membrana específica da próstata para endo radioterapia de cancro da próstata |
| US20210276971A1 (en) * | 2018-06-20 | 2021-09-09 | The Research Foundation For The State University Of New York | Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same |
-
2019
- 2019-03-29 DK DK19775196.9T patent/DK3778592T3/da active
- 2019-03-29 SG SG11202009649RA patent/SG11202009649RA/en unknown
- 2019-03-29 BR BR112020019566-9A patent/BR112020019566A2/pt active Search and Examination
- 2019-03-29 MY MYPI2020004923A patent/MY197419A/en unknown
- 2019-03-29 PL PL19775196.9T patent/PL3778592T3/pl unknown
- 2019-03-29 RS RS20230503A patent/RS64296B1/sr unknown
- 2019-03-29 EP EP19775196.9A patent/EP3778592B1/en active Active
- 2019-03-29 JP JP2021502679A patent/JP7094591B2/ja active Active
- 2019-03-29 PT PT197751969T patent/PT3778592T/pt unknown
- 2019-03-29 CN CN201980023911.7A patent/CN112004812B/zh active Active
- 2019-03-29 KR KR1020190037293A patent/KR102156385B1/ko active IP Right Grant
- 2019-03-29 CA CA3094620A patent/CA3094620C/en active Active
- 2019-03-29 ES ES19775196T patent/ES2947748T3/es active Active
- 2019-03-29 HR HRP20230604TT patent/HRP20230604T1/hr unknown
- 2019-03-29 WO PCT/KR2019/003716 patent/WO2019190266A1/ko unknown
- 2019-03-29 LT LTEPPCT/KR2019/003716T patent/LT3778592T/lt unknown
- 2019-03-29 US US16/981,432 patent/US11931431B2/en active Active
- 2019-03-29 AU AU2019243408A patent/AU2019243408B2/en active Active
- 2019-03-29 FI FIEP19775196.9T patent/FI3778592T3/fi active
- 2019-03-29 MX MX2020010266A patent/MX2020010266A/es unknown
- 2019-03-29 SI SI201930575T patent/SI3778592T1/sl unknown
- 2019-03-29 EA EA202092333A patent/EA202092333A1/ru unknown
- 2019-03-29 HU HUE19775196A patent/HUE062904T2/hu unknown
-
2020
- 2020-09-15 PH PH12020551471A patent/PH12020551471A1/en unknown
- 2020-09-28 CL CL2020002510A patent/CL2020002510A1/es unknown
- 2020-09-29 ZA ZA2020/06008A patent/ZA202006008B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202006008B (en) | 2021-10-27 |
| KR102156385B1 (ko) | 2020-09-15 |
| BR112020019566A2 (pt) | 2021-01-05 |
| EA202092333A1 (ru) | 2021-01-21 |
| WO2019190266A1 (ko) | 2019-10-03 |
| SG11202009649RA (en) | 2020-10-29 |
| MX2020010266A (es) | 2020-11-06 |
| CA3094620C (en) | 2022-11-22 |
| MY197419A (en) | 2023-06-16 |
| EP3778592A1 (en) | 2021-02-17 |
| EP3778592B1 (en) | 2023-04-26 |
| CN112004812A (zh) | 2020-11-27 |
| SI3778592T1 (sl) | 2023-08-31 |
| LT3778592T (lt) | 2023-06-26 |
| PH12020551471A1 (en) | 2021-09-01 |
| DK3778592T3 (da) | 2023-06-19 |
| AU2019243408A1 (en) | 2020-10-29 |
| US20210106701A1 (en) | 2021-04-15 |
| US11931431B2 (en) | 2024-03-19 |
| CN112004812B (zh) | 2023-05-26 |
| HUE062904T2 (hu) | 2023-12-28 |
| EP3778592A4 (en) | 2021-02-17 |
| FI3778592T3 (fi) | 2023-06-19 |
| JP7094591B2 (ja) | 2022-07-04 |
| CA3094620A1 (en) | 2019-10-03 |
| CL2020002510A1 (es) | 2021-02-19 |
| AU2019243408B2 (en) | 2021-10-14 |
| ES2947748T3 (es) | 2023-08-17 |
| PL3778592T3 (pl) | 2023-11-27 |
| PT3778592T (pt) | 2023-06-19 |
| KR20190114908A (ko) | 2019-10-10 |
| JP2021519822A (ja) | 2021-08-12 |
| RS64296B1 (sr) | 2023-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230604T1 (hr) | Radiofarmaceutik usmjeren na psma, namijenjen dijagnosticiranju i liječenju raka prostate | |
| HRP20221195T1 (hr) | Spojevi koji ciljaju psma i njihova uporaba | |
| CN100422180C (zh) | 淀粉样斑块聚集抑制剂和诊断成像剂 | |
| CA2440559A1 (en) | Novel non-imidazole compounds | |
| GEP20237497B (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer | |
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| HRP20080150T4 (hr) | Postupak za proizvodnju krutog farmaceutskog sastava koji sadrži 5-klor-n-({(5s)-2-oksa-3-[4-(3-okso-4-morfolinil)-fenil]-1,3-oksazolidin-5-il}-metil)-2-tiofenkarboksamid i koji se može aplicirati oralno | |
| Meegalla et al. | Tc-99m-labeled tropanes as dopamine transporter imaging agents | |
| DK1294402T3 (da) | Forbindelser med en sulfonamidgruppe og farmaceutiske præparater indeholdende disse forbindelser | |
| ATE482961T1 (de) | Hydrogensulfat von 2-acetoxy-5-(a- cyclopropylcarbonyl-2-fluorbenzyl)-4,5,6,7- tetrahydrothienoä3,2-cüpyridin und dessen zubereitung | |
| JP2022108241A5 (hr) | ||
| TW200635942A (en) | 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceurical preparations that contain the latter | |
| HRP20171763T1 (hr) | Derivati piridin-4-ila | |
| CN109641898A (zh) | 用于治疗神经和神经退行性疾病的5,7-二氢-吡咯并-吡啶衍生物 | |
| HRP20170735T1 (hr) | Oksidirani avidin s dugim trajanjem zadržavanja u obrađenim tkivima | |
| HRP20171149T1 (hr) | Oralni farmaceutski pripravak koji sadrži tvar za prikrivanje ukusa n-acetilcisteina | |
| HRP20211836T1 (hr) | Novi spoj koji sadrži dušik ili njegova sol, ili njegov metalni kompleks | |
| HRP20210576T1 (hr) | 5-[[4-[2-[5-(1-hidroksietil)piridin-2-il]etoksi]fenil]metil]-1,3-tiazolidin-2,4-dion, namijenjen liječenju nealkoholne masne bolesti jetre | |
| JP2021504326A5 (hr) | ||
| CN204946454U (zh) | 耳石症解剖教学模具 | |
| AR023934A1 (es) | Compuesto que consta de un derivado de benzodiacepina que se liga con un receptor iib/iiia de glicoproteina, composicion farmaceutica, agentecentellografico para la formacion de imagenes, complejo de un radionuclido emisor de y, quelado 99m tc de un compuesto que comprende una benzodiacepina, metodo | |
| JP2010540627A5 (hr) | ||
| JP2019523294A5 (hr) | ||
| BR0007473A (pt) | Composições tendo estabilidade melhorada | |
| ME01464B (me) | Novi postupak za sintetiziranje ivabradina i njegovih adicijskih soli |